Figure 3 | Scientific Reports

Figure 3

From: Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Figure 3

Cost-effectiveness acceptability curve and frontier; y-axis values indicate the probability of a strategy being cost-effective across a wide range of willingness-to-pay thresholds. The solid vertical line represents the willingness-to-pay threshold of CNY 216,000 per QALY. The dashed vertical line represents CNY 72,100 per QALY. CNY, Chinese Yuan Renminbi.

Back to article page